查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403455

到 2030 年抗癫痫药物市场预测：按癫痫类型、给药途径、药物生成、配销通路和地区进行的全球市场分析

Antiepileptic Drugs Market Forecasts to 2030 - Global Analysis By Types of Seizures, Route of Administration, Drug Generation, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球抗癫痫药物市场规模为 185 亿美元，预计 2030 年将达到 287 亿美元，预测期内复合年增长率为 6.5%。

癫痫是一种神经系统疾病，其特征是由大脑异常电活动引起的反覆、不可预测的癫痫发作。抗癫痫药物的作用是调节大脑的电活动，预防或减少导致癫痫发作的异常衝动。 AED 可稳定细胞膜、增强 GABA 等抑制性神经传导物质、阻断钠通道、降低麸胺酸兴奋性或调节钙离子通道。

根据世界卫生组织（WHO）2023年2月9日公布，全球每年有500万人被诊断出患有癫痫症。据估计，高所得国家每 10 万人中就有 49 人患有癫痫。

药物开发的进展

持续的研究和开发工作正在发现新的剂型、新的作用机制和改进的药物传输系统，这些正在改变抗癫痫治疗的模式。引入下一代抗癫痫药物旨在解决传统治疗方法的局限性，例如副作用和癫痫控制不完全。此外，包括缓释製剂在内的缓释性製剂正在改善给药方案并提高患者的医嘱遵从性和整体治疗效果。药物开发的这些进步正在推动市场需求。

副作用

常见的副作用包括头晕、疲劳、认知障碍和情绪变化，这些都会显着影响患者的生活品质。面临的挑战是平衡癫痫控制的治疗益处与这些副作用的耐受性。此外，副作用的发生可能导致患者不满意、违规和停止治疗，从而抑制抗癫痫治疗的有效性。这些副作用是主要的抑制因素和阻碍市场扩张。

癫痫盛行率上升

癫痫是一种以反覆发作为特征的神经系统疾病，影响着全世界大量患者。癫痫盛行率的上升是由多种因素造成的。首先，诊断技术的改进和对癫痫意识的提高有助于提高检出率。医学知识和技术的进步使医疗保健专业人员能够准确诊断和分类癫痫。宣传宣传活动和教育计划也传播了有关癫痫症状和早期诊断重要性的知识，增加了寻求医疗护理的人数。

社会耻辱

儘管对神经系统疾病癫痫的认识取得了进展，但社会误解仍然存在，也是人们不愿意接受适当治疗的因素。围绕癫痫的耻辱可能会导致诊断和治疗的延误，有些人因为害怕社会判断或歧视而避免透露自己的病情或寻求医疗帮助。不愿在公共场合谈论癫痫可能会加剧资讯，阻止患者接受必要且有效的抗癫痫药物治疗，并妨碍患者教育。这些因素抑制了市场需求。

COVID-19 的影响

COVID-19 大流行严重影响了抗癫痫药物 (AED) 市场。这场大流行凸显了确保医疗保健系统具有弹性的重要性。远端医疗解决方案和远端患者监护已成为人们关注的焦点，为癫痫管理提供了另一种方法。此外，我们对解决 COVID-19 神经系统併发症的研究和开发的关注间接有助于更好地了解癫痫及相关疾病。此外，供应链中断和经济不确定性正在影响 AED 的生产和分销，进而影响市场动态。

预计第三代细分市场在预测期内将是最大的

第三代细分市场预计将占据最大份额。这些药物，包括拉科酰胺、艾斯利卡西平和吡崙帕奈，在治疗癫痫发作方面显示出更高的特异性和有效性。第三代 AED 通常针对新的分子途径，从而产生频谱作用和调节神经元活动的高选择性。第三代 AED 的主要特点之一是注重最大限度地减少副作用和药物交互作用，从而提高整体耐受性。这对于提高患者对治疗方法的医嘱遵从性尤其重要。

预计口腔细分市场在预测期内复合年增长率最高

预计口服药物领域在预测期内将出现良好的成长。口服给药时，抗癫痫药物以锭剂、胶囊或液体的形式服用，使得药物从胃肠道吸收方便、有效率。口服给药为药物製剂提供了弹性，并允许开发随时间逐渐释放药物的缓释缓释性。此功能可保持血液中的药物浓度恆定，优化治疗效果并最大限度地减少可能引发癫痫发作的波动。

占比最高的地区

由于强大的医疗基础设施、先进的医学研究和癫痫相关疾病的高盛行率，北美在预测期内占据了最大的市场占有率。该地区的製药业十分完善，在研发方面的大量投资推动了抗癫痫治疗的创新。此外，主要市场参与者的存在和最尖端科技的采用有助于该地区在推进治疗方案方面处于领先地位。

复合年增长率最高的地区：

由于认识的提高、医疗基础设施的改善以及癫痫相关疾病盛行率的上升，预计亚太地区在预测期内将实现盈利增长。向更好的诊断和加强患者教育的转变进一步推动了该地区抗癫痫药物的需求。此外，该地区多样化的人口结构和强大的患者基础为参与抗癫痫药物开发和销售的製药公司提供了巨大的成长机会。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球抗癫痫药物市场：依癫痫类型

  • 局部性发作
  • 整体癫痫发作
  • 其他类型的癫痫发作

第六章全球抗癫痫药物市场：依给药途径分类

  • 静脉
  • 口服
  • 其他给药途径

第七章 全球抗癫痫药物市场：新药生成

  • 第一代
    • Carbamazepine
    • 苯妥英
    • 丙戊酸
    • 奥卡西平
    • 乙舒酰亚胺
    • 托吡酯
    • 扑米酮
    • 苯巴比妥
  • 第二代
    • 普瑞巴林
    • 拉莫三嗪
    • 左乙拉西坦
    • 卢非酰胺
    • 醋酸艾斯利卡西平
    • 拉科酰胺
    • 吡崙帕奈
    • 唑尼沙胺
  • 第三代

第八章全球抗癫痫药物市场：依配销通路

  • 零售药房
  • 医院药房
  • 网路药房
  • 其他配销通路

第九章全球抗癫痫药物市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Eisai Co., Ltd.
  • Novartis AG
  • Merck KGaA
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca
  • Abbott
  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories Ltd.
  • Johnson & Johnson Service, Inc.
  • Zogenix
  • Alkem Labs
  • SK Biopharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
Product Code: SMRC24680

According to Stratistics MRC, the Global Antiepileptic Drugs Market is accounted for $18.5 billion in 2023 and is expected to reach $28.7 billion by 2030 growing at a CAGR of 6.5% during the forecast period. Epilepsy is a neurological disorder characterized by recurrent and unpredictable seizures, which are caused by abnormal electrical activity in the brain. Antiepileptic drugs work by modulating the electrical activity in the brain, preventing or reducing abnormal impulses that lead to seizures. AEDs stabilize cell membranes, enhance inhibitory neurotransmitters like GABA, block sodium channels, reduce glutamate excitability, or modulate calcium channels.

According to World Health Organization (WHO) on February 09, 2023, 5 million people are diagnosed globally with epilepsy every year. Epilepsy is estimated to affect 49 persons out of every 100,000 in high-income countries every year.

Market Dynamics:

Driver:

Advancements in drug development

Continuous research and development efforts have led to the discovery of new formulations, novel mechanisms of action, and improved drug delivery systems, revolutionizing the landscape of antiepileptic treatments. The introduction of next-generation antiepileptic drugs has aimed to address limitations associated with traditional therapies, such as adverse side effects and incomplete seizure control. Additionally, advanced formulations, including extended-release versions, offer improved dosing regimens, enhancing patient adherence and overall treatment efficacy. These advancements in drug development propel market demand.

Restraint:

Side effects

Common side effects include dizziness, fatigue, cognitive impairment, and mood alterations, which can significantly impact patients' quality of life. The challenge lies in balancing the therapeutic benefits of seizure control with the tolerability of these side effects. Moreover, the occurrence of adverse reactions may lead to patient dissatisfaction, non-compliance, or discontinuation of treatment, impeding the effectiveness of antiepileptic therapy. These side effects pose a significant restraint, hampering market expansion.

Opportunity:

Rising prevalence of epilepsy

Epilepsy is a neurological disorder characterized by recurrent seizures, and it affects a substantial number of individuals worldwide. The rising prevalence of epilepsy can be attributed to several factors. Firstly, improved diagnostic techniques and increased awareness of epilepsy have contributed to a higher detection rate. As medical knowledge and technological advancements have improved, healthcare professionals are better equipped to diagnose and classify epilepsy accurately. Additionally, awareness campaigns and educational programs have helped spread knowledge about epilepsy symptoms and the importance of early diagnosis, leading to more individuals seeking medical attention.

Threat:

Social stigma

Despite advancements in understanding the neurological condition, societal misconceptions persist, contributing to reluctance among individuals to seek appropriate treatment. The stigma surrounding epilepsy may lead to under diagnosis and under treatment, as some individuals may avoid disclosing their condition or seeking medical help due to fear of social judgment or discrimination. This unwillingness to discuss epilepsy in public can worsen misinformation, prevent patients from receiving the necessary and efficient treatment that antiepileptic medications provide, and impede patient education. These factors impede market demand.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the Antiepileptic Drugs (AEDs) market. Pandemic has underscored the importance of ensuring a resilient healthcare system. Telehealth solutions and remote patient monitoring have gained prominence, providing alternative avenues for epilepsy management. Additionally, the focus on research and development to address neurological complications of COVID-19 has indirectly contributed to advancements in understanding epilepsy and related disorders. Moreover, supply chain disruptions and economic uncertainties have impacted the production and distribution of AEDs, affecting market dynamics.

The third generation segment is expected to be the largest during the forecast period

The third generation segment is estimated to hold the largest share. These drugs, such as lacosamide, eslicarbazepine, and perampanel, exhibit enhanced specificity and efficacy in managing epileptic seizures. Third-generation AEDs often target novel molecular pathways, providing a broader spectrum of action and greater selectivity in modulating neuronal activity. One key feature of third-generation AEDs is their focus on minimizing side effects and drug interactions, thus improving overall tolerability. This is particularly important in enhancing patient adherence to treatment regimens.

The Oral segment is expected to have the highest CAGR during the forecast period

The Oral segment is anticipated to have lucrative growth during the forecast period. Oral administration involves the ingestion of antiepileptic drugs in the form of tablets, capsules, or liquids, allowing for convenient and efficient drug absorption through the gastrointestinal tract. The oral route provides flexibility in drug formulation, enabling the development of extended-release formulations that release the medication gradually over time. This feature helps maintain consistent drug levels in the bloodstream, optimizing therapeutic efficacy and minimizing fluctuations that could trigger seizures.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to robust healthcare infrastructure, advanced medical research, and a high prevalence of epilepsy-related disorders. The region's well-established pharmaceutical industry, coupled with substantial investments in research and development, fosters innovation in antiepileptic treatments. Moreover, the presence of key market players and the adoption of cutting-edge technologies contribute to the region's leadership in advancing treatment options.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period, due to increasing awareness, growing healthcare infrastructure, and a rising incidence of epilepsy-related disorders. A shift towards better diagnostics and increased patient education further fuels the demand for antiepileptic medications in this region. Additionally, with a diverse demographic and a substantial patient base, the region represents a significant growth opportunity for pharmaceutical companies engaged in the development and distribution of antiepileptic drugs.

Key players in the market:

Some of the key players in the Antiepileptic Drugs Market include Eisai Co., Ltd., Novartis AG, Merck KGaA, Teva Pharmaceutical Industries Ltd., AstraZeneca, Abbott, Sanofi, Pfizer Inc., GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd., Johnson & Johnson Service, Inc., Zogenix, Alkem Labs, SK Biopharmaceuticals and Sun Pharmaceutical Industries Ltd.

Key Developments:

In June 2023, Pfizer announced a strategic collaboration with Truveta to deliver new safety insights on a continuous basis, using verifiable real-world data at scale.

In January 2021, Novartis announced collaboration with Alnylam to leverage Alnylam's proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.

Types of Seizures Covered:

  • Partial-onset seizures
  • Generalized seizures
  • Other Types of Seizures

Route of Administrations Covered:

  • Intravenous
  • Oral
  • Other Route of Administrations

Drug Generations Covered:

  • First Generation
  • Second Generation
  • Third Generation

Distribution Channels Covered:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Antiepileptic Drugs Market, By Types of Seizures

  • 5.1 Introduction
  • 5.2 Partial-onset seizures
  • 5.3 Generalized seizures
  • 5.4 Other Types of Seizures

6 Global Antiepileptic Drugs Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Intravenous
  • 6.3 Oral
  • 6.4 Other Route of Administrations

7 Global Antiepileptic Drugs Market, By Drug Generation

  • 7.1 Introduction
  • 7.2 First Generation
    • 7.2.1 Carbamazepine
    • 7.2.2 Phenytoin
    • 7.2.3 Valproate
    • 7.2.4 Oxycarbazepine
    • 7.2.5 Ethosuximide
    • 7.2.6 Topiramate
    • 7.2.7 Primidone
    • 7.2.8 Phenobarbital
  • 7.3 Second Generation
    • 7.3.1 Pregabalin
    • 7.3.2 Lamotrigine
    • 7.3.3 Levetiracetam
    • 7.3.4 Rufinamide
    • 7.3.5 Eslicarbazepine acetate
    • 7.3.6 Lacosamide
    • 7.3.7 Perampanel
    • 7.3.8 Zonisamide
  • 7.4 Third Generation

8 Global Antiepileptic Drugs Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacies
  • 8.3 Hospital Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Other Distribution Channels

9 Global Antiepileptic Drugs Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Eisai Co., Ltd.
  • 11.2 Novartis AG
  • 11.3 Merck KGaA
  • 11.4 Teva Pharmaceutical Industries Ltd.
  • 11.5 AstraZeneca
  • 11.6 Abbott
  • 11.7 Sanofi
  • 11.8 Pfizer Inc.
  • 11.9 GlaxoSmithKline plc
  • 11.10 Dr. Reddy's Laboratories Ltd.
  • 11.11 Johnson & Johnson Service, Inc.
  • 11.12 Zogenix
  • 11.13 Alkem Labs
  • 11.14 SK Biopharmaceuticals
  • 11.15 Sun Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Antiepileptic Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Antiepileptic Drugs Market Outlook, By Types of Seizures (2021-2030) ($MN)
  • Table 3 Global Antiepileptic Drugs Market Outlook, By Partial-onset seizures (2021-2030) ($MN)
  • Table 4 Global Antiepileptic Drugs Market Outlook, By Generalized seizures (2021-2030) ($MN)
  • Table 5 Global Antiepileptic Drugs Market Outlook, By Other Types of Seizures (2021-2030) ($MN)
  • Table 6 Global Antiepileptic Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 7 Global Antiepileptic Drugs Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 8 Global Antiepileptic Drugs Market Outlook, By Oral (2021-2030) ($MN)
  • Table 9 Global Antiepileptic Drugs Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 10 Global Antiepileptic Drugs Market Outlook, By Drug Generation (2021-2030) ($MN)
  • Table 11 Global Antiepileptic Drugs Market Outlook, By First Generation (2021-2030) ($MN)
  • Table 12 Global Antiepileptic Drugs Market Outlook, By Carbamazepine (2021-2030) ($MN)
  • Table 13 Global Antiepileptic Drugs Market Outlook, By Phenytoin (2021-2030) ($MN)
  • Table 14 Global Antiepileptic Drugs Market Outlook, By Valproate (2021-2030) ($MN)
  • Table 15 Global Antiepileptic Drugs Market Outlook, By Oxycarbazepine (2021-2030) ($MN)
  • Table 16 Global Antiepileptic Drugs Market Outlook, By Ethosuximide (2021-2030) ($MN)
  • Table 17 Global Antiepileptic Drugs Market Outlook, By Topiramate (2021-2030) ($MN)
  • Table 18 Global Antiepileptic Drugs Market Outlook, By Primidone (2021-2030) ($MN)
  • Table 19 Global Antiepileptic Drugs Market Outlook, By Phenobarbital (2021-2030) ($MN)
  • Table 20 Global Antiepileptic Drugs Market Outlook, By Second Generation (2021-2030) ($MN)
  • Table 21 Global Antiepileptic Drugs Market Outlook, By Pregabalin (2021-2030) ($MN)
  • Table 22 Global Antiepileptic Drugs Market Outlook, By Lamotrigine (2021-2030) ($MN)
  • Table 23 Global Antiepileptic Drugs Market Outlook, By Levetiracetam (2021-2030) ($MN)
  • Table 24 Global Antiepileptic Drugs Market Outlook, By Rufinamide (2021-2030) ($MN)
  • Table 25 Global Antiepileptic Drugs Market Outlook, By Eslicarbazepine acetate (2021-2030) ($MN)
  • Table 26 Global Antiepileptic Drugs Market Outlook, By Lacosamide (2021-2030) ($MN)
  • Table 27 Global Antiepileptic Drugs Market Outlook, By Perampanel (2021-2030) ($MN)
  • Table 28 Global Antiepileptic Drugs Market Outlook, By Zonisamide (2021-2030) ($MN)
  • Table 29 Global Antiepileptic Drugs Market Outlook, By Third Generation (2021-2030) ($MN)
  • Table 30 Global Antiepileptic Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 31 Global Antiepileptic Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 32 Global Antiepileptic Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 33 Global Antiepileptic Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 34 Global Antiepileptic Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.